These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1371908)

  • 41. All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis.
    Qu ZX; Dayal A; Jensen MA; Arnason BG
    Arch Neurol; 1998 Mar; 55(3):315-21. PubMed ID: 9520005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leukocytes from multiple sclerosis patients respond to alpha- and gamma-interferons.
    Kamin-Lewis RM; Panitch HS; Johnson KP
    J Neuroimmunol; 1985 Aug; 9(3-4):221-7. PubMed ID: 2410451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis.
    Brod SA; Kerman RH; Nelson LD; Marshall GD; Henninger EM; Khan M; Jin R; Wolinsky JS
    Mult Scler; 1997 Feb; 3(1):1-7. PubMed ID: 9160341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon response heterogeneity: activation of a pro-inflammatory response by interferon alpha and beta. A possible basis for diverse responses to interferon beta in MS.
    Jansen M; Reinhard JF
    J Leukoc Biol; 1999 Apr; 65(4):439-43. PubMed ID: 10204571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [T-lymphocytes with a receptor for the immunoglobulin Fc fragment in the blood of multiple sclerosis patients].
    Czernicki J; Rzetelski B
    Neurol Neurochir Pol; 1981; 15(5-6):559-64. PubMed ID: 6210849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellular response to basic protein and T suppressor cells in multiple sclerosis.
    Wicher V; Holub R
    Immunol Commun; 1982; 11(6):495-507. PubMed ID: 6188680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intermittent interferonemia and interferon responses in multiple sclerosis.
    Hertzog PJ; Wright A; Harris G; Linnane AW; Mackay IR
    Clin Immunol Immunopathol; 1991 Jan; 58(1):18-32. PubMed ID: 1701372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Suppressor cell activity in multiple sclerosis.
    Wallen WC; Houff SA; Iivanainen M; Calabrese VP; DeVries GH
    Neurology; 1981 Jun; 31(6):668-74. PubMed ID: 6454082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon as a mediator of human lymphocyte suppression.
    Kadish AS; Tansey FA; Yu GS; Doyle AT; Bloom BR
    J Exp Med; 1980 Mar; 151(3):637-50. PubMed ID: 6444662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinico-immunological comparisons in evaluation of interferon system functioning in patients with multiple sclerosis].
    Kobiakina NA; Chekneva NS; Mezentseva MV; Narovlianskiĭ AN; Cheknev SB; Skvortsova VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(11):38-42. PubMed ID: 12497995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro.
    Hirsch RL; Panitch HS; Johnson KP
    J Clin Immunol; 1985 Nov; 5(6):386-9. PubMed ID: 3936865
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T-lymphocyte immunointerferon receptors in patients with multiple sclerosis.
    Bongioanni P; Lombardo F; Fioretti C; Meucci G
    J Neurol; 1996 Aug; 243(8):605-10. PubMed ID: 8865028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Endogenous biological retranslation in current clinical and biological studies].
    Cheknev SB
    Vestn Ross Akad Med Nauk; 2003; (4):28-34. PubMed ID: 12741357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural alpha interferon.
    Kamin-Lewis RM; Panitch HS; Merigan TC; Johnson KP
    J Interferon Res; 1984; 4(3):423-32. PubMed ID: 6333472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferons and multiple sclerosis.
    Clanet M; Blancher A; Calvas P; Rascol O
    Biomed Pharmacother; 1989; 43(5):355-60. PubMed ID: 2477075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Suppressor cell function in multiple sclerosis.
    Arnason BG; Antel J
    Ann Immunol (Paris); 1978; 129(2-3):159-70. PubMed ID: 677810
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical trials of interferons in multiple sclerosis. What have we learned?
    Panitch HS; Bever CT
    J Neuroimmunol; 1993 Jul; 46(1-2):155-64. PubMed ID: 7689585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients.
    Kaser A; Deisenhammer F; Berger T; Tilg H
    Lancet; 1999 Apr; 353(9162):1413-4. PubMed ID: 10227230
    [No Abstract]   [Full Text] [Related]  

  • 59. Activated suppressor cell function in multiple sclerosis--clinical correlations.
    Antel J; Brown M; Nicholas MK; Blain M; Noronha A; Reder A
    J Neuroimmunol; 1988 Mar; 17(4):323-30. PubMed ID: 2963018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.
    Medenica RD; Mukerjee S; Alonso K; Lazovic G; Huschart T
    J Clin Apher; 1994; 9(4):222-7. PubMed ID: 7538999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.